The estimated stock exchanges were observed around 29.93 USD in the share market for NasdaqGS for the PLRX. Since Pliant Therapeutics held a successful IPO earlier in June, that raised an enticing amount of $144 million. Though the much-upsized amount still feels like a pea size in front of Moderna’s $604 million IPO, questions have started to raise: Could Pliant become the next Moderna.
Pliant’s (NASDAQ: PLRX at https://www.webull.com/quote/nasdaq-plrx) niche is the development of drugs that target fibrotic diseases, focusing over inhibition of integrin proteins suitable for releasing transforming growth bacteria beta 1 ( TGF beta 1), which further regulates the wound repairs but can cause fibrosis.
Possibilities are there for Pliant (NASDAQ: PLRX) to become one of those next biotech investors. If Pliant’s experimental drugs become successful, there is a high possibility that the stocks could make early investors quite wealthier over time as there’s a tremendous need in the treatment of fibrosis diseases.
NASDAQ comes under the second rank after the New York Stock Exchange (NYSE) in stocks and securities exchange. Its trade takes place through an electronic medium with the help of suitable dealers. Hence, in turn, it attracts more tech-growth oriented businesses than any other exchanges. Moreover, NASDAQ was the first electronic stock market of the world established in the year 1971 by the Nation Association of Securities Dealers (NASD). It stands for the National Association of Securities Dealers Automated Quotations.
Its quotations are available in the three tiers as levels:
- Level 1: Showing highest bid and lowest ask
- Level 2: Sowing all public quotes of market makers together along with info of the market dealers who wish for stock exchange under recently executed orders.
- Level 3: Used by the market makers. Allows them to enter their respective quotes and in executing further orders.
The Pliant Therapeutics Inc. (NASDAQ: PLRX) is a biopharmaceutical company, involved in the discovery and development of novel therapies against certain fibrotic diseases. Pliant’s (NASDAQ: PLRX) co-founders comprise world-renowned researchers from various states including the University of California, San Francisco, bringing broad experience in fibrosis biology and molecular chemistry. Together, the team is dedicated to the translation of scientific advantages in fibrosis biology into novel therapies for needy patients. Founded on 6 August 2025 the Pliant Therapeutics (NASDAQ: PLRX) is focused on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
It was founded by Bradley Bakes, Bill De Grasp, HAL Chapman and Dean Shepherd in June 2015 and headquarters are in South San Francisco, CA. The current price of the organization is estimated at around 1379101 USD. You can do stock trade from the best day trading platform. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.